6-溴-2H-苯并[b][1,4]噁嗪-4(3h)-羧酸叔丁酯 | 719310-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 6-溴-2H-苯并[b][1,4]噁嗪-4(3h)-羧酸叔丁酯
• 中文别名: 6-溴-2H-苯并[b][1,4]噁嗪-4(3H)-羧酸叔丁酯；叔丁基-6-溴-2,3-二氢苯并[b][1,4]恶嗪-4-甲酸叔丁酯；N-BOC-6-溴苯[B]并吗啉
• 英文名称: tert-butyl 6-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
• 英文别名: tert-butyl 6-bromo-2,3-dihydrobenzo[b][1,4]oxazine-4-carboxylate；tert-Butyl 6-bromo-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate；tert-butyl 6-bromo-2,3-dihydro-1,4-benzoxazine-4-carboxylate
• CAS: 719310-31-3
• 化学式: C₁₃H₁₆BrNO₃
• 分子量: 314.179
• InChiKey: JOFHRALTEXLLIC-UHFFFAOYSA-N

物化性质

• 沸点：
  377.7±42.0 °C(Predicted)
• 密度：
  1.416±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-BOC-6-Bromo-2,3-dihydro-1,4-benzoxazine
Synonyms: Tert-butyl 6-bromo-2,3-dihydro-1,4-benzoxazine-4-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-BOC-6-Bromo-2,3-dihydro-1,4-benzoxazine
CAS number: 719310-31-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H16BrNO3
Molecular weight: 314.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-2H-苯并[b][1,4]噁嗪-4(3h)-羧酸叔丁酯 在 正丁基锂 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 97.5h， 生成 (3S,4S)-2-(4-(tert-butyl)-3-chlorophenyl)-3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylic acid
  参考文献：
  名称：

  [EN] OXO-TETRAHYDRO-ISOQUINOLINE CARBOXYLIC ACIDS AS STING INHIBITORS
  [FR] ACIDES OXO-TÉTRAHYDRO-ISOQUINOLINE CARBOXYLIQUES EN TANT QU'INHIBITEURS DE LA PROTÉINE STING

  摘要：

  本发明提供了一种式I的化合物，这些化合物是STING抑制剂，因此可用于治疗STING介导的疾病，如炎症、哮喘、慢性阻塞性肺病（COPD）和癌症。

  公开号：

  WO2019182886A1
• 作为产物：
  描述：

  4-溴-2-硝基苯酚 在 4-二甲氨基吡啶 、 乙醇 、 potassium carbonate 、 三乙胺 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 6-溴-2H-苯并[b][1,4]噁嗪-4(3h)-羧酸叔丁酯
  参考文献：
  名称：

  [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  [FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS

  摘要：

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。

  公开号：

  WO2011130628A1

文献信息

• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS<br/>[FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS
  申请人：CURIS INC

  公开号：WO2011130628A1

  公开（公告）日：2011-10-20

  The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。
• [EN] ISOINDOLINES AS HDAC INHIBITORS<br/>[FR] ISOINDOLINES UTILISÉES COMME INHIBITEURS DE HDAC
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2019204550A1

  公开（公告）日：2019-10-24

  The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

  本公开涉及抑制锌依赖性组蛋白去乙酰化酶（HDACs）的抑制剂，其化学式如下：（I）其中Z、X1、X2、Y1、Y2、Y3、L、Z和R如本文所述。
• [EN] BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS<br/>[FR] BENZOXAZINES ET LEURS DERIVES EN TANT QU'INHIBITEURS DE PI3KS
  申请人：WARNER LAMBERT CO

  公开号：WO2004056820A1

  公开（公告）日：2004-07-08

  The present invention provides compounds of Formula (I) wherein W, Q, E, D, A, L, R6, R7, R8, Y, K, R9, R10, G, the dashed bond between D and E, and the double bond denoted '*' have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I).

  本发明提供了化合物的公式（I），其中W、Q、E、D、A、L、R6、R7、R8、Y、K、R9、R10、G、D和E之间的虚线键，以及表示'*'的双键，在规范中定义了任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药剂，包括炎症性疾病、心血管疾病和癌症。还提供了包含一个或多个公式（I）化合物的药物组合物。
• Benzoxazines and derivatives thereof as therapeutic agents
  申请人：——

  公开号：US20040138199A1

  公开（公告）日：2004-07-15

  The present invention provides compounds of Formula I 1 wherein W, Q, E, D, A, L, R 6 , R 7 , R 8 , Y, K, R 9 , R 10 , G, the dashed bond between D and E, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

  本发明提供了公式I1中的化合物，其中W、Q、E、D、A、L、R6、R7、R8、Y、K、R9、R10、G、D和E之间的虚线键以及表示为“*”的双键具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病、心血管疾病和癌症。还提供了包含一个或多个公式I中的化合物的制药组合物。